10088250.trn 10/21/2004

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1626GMS

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	Jul 12	BEILSTEIN enhanced with new display and select options, resulting in a closer connection to BABS
NEWS	4	AUG 02	IFIPAT/IFIUDB/IFICDB reloaded with new search and display fields
NEWS	5	AUG 02	CAplus and CA patent records enhanced with European and Japan Patent Office Classifications
NEWS	6	AUG 02	The Analysis Edition of STN Express with Discover! (Version 7.01 for Windows) now available
NEWS	7	AUG 27	BIOCOMMERCE: Changes and enhancements to content coverage
NEWS	8	AUG 27	BIOTECHABS/BIOTECHDS: Two new display fields added for legal status data from INPADOC
NEWS	9	SEP 01	INPADOC: New family current-awareness alert (SDI) available
NEWS	10	SEP 01	New pricing for the Save Answers for SciFinder Wizard within STN Express with Discover!
NEWS	11	SEP 01	New display format, HITSTR, available in WPIDS/WPINDEX/WPIX
NEWS	12	SEP 27	STANDARDS will no longer be available on STN
NEWS	13	SEP 27	SWETSCAN will no longer be available on STN

NEWS EXPRESS	JULY 30 CURRENT WINDOWS VERSION IS V7.01, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 11 AUGUST 2004
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 08:54:27 ON 21 OCT 2004

=>
Uploading

THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE
Do you want to switch to the Registry File?
Choice (Y/n):
Switching to the Registry File...
Some commands only work in certain files. For example, the EXPAND command can only be used to look at the index in a file which has an index. Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of commands which can be used in this file.

=> FILE REGISTRY

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 08:54:39 ON 21 OCT 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 20 OCT 2004 HIGHEST RN 766487-31-4
DICTIONARY FILE UPDATES: 20 OCT 2004 HIGHEST RN 766487-31-4

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading C:\Program Files\Stnexp\Queries\10088250.str



chain nodes :
16 17 18 19 20
ring nodes :
1 2 3 4 5 6 7 8 10 11 12 13 14 15
chain bonds :
2-14 16-17 17-18 18-19 19-20
ring bonds :

1-6 1-3 2-5 2-3 4-5 4-8 5-6 6-7 7-8 10-11 10-15 11-12 12-13 13-14
14-15
exact/norm bonds :
1-6 1-3 2-5 2-3 2-14 4-5 4-8 5-6 6-7 7-8 16-17 17-18 18-19 19-20
normalized bonds :
10-11 10-15 11-12 12-13 13-14 14-15
isolated ring systems :
containing 1 : 10 :

G1:O,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 10:Atom 11:Atom
12:Atom 13:Atom 14:Atom 15:Atom 16:CLASS 17:CLASS 18:CLASS 19:CLASS
20:CLASS 22:CLASS

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 O,N

Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 08:54:58 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 8 TO ITERATE

100.0% PROCESSED 8 ITERATIONS 5 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 8 TO 329
PROJECTED ANSWERS: 5 TO 234

L2 5 SEA SSS SAM L1

=> s l1 sss full
FULL SEARCH INITIATED 08:55:04 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 201 TO ITERATE

100.0% PROCESSED 201 ITERATIONS 131 ANSWERS
SEARCH TIME: 00.00.01

L3 131 SEA SSS FUL L1

=> FIL CAPLUS
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	155.42	155.63

FILE 'CAPLUS' ENTERED AT 08:55:13 ON 21 OCT 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 21 Oct 2004 VOL 141 ISS 17
FILE LAST UPDATED: 20 Oct 2004 (20041020/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3
L4 3 L3

=> d l4 ibib abs hitstr tot

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2001:208282 CAPLUS
DOCUMENT NUMBER: 134:237472
TITLE: Preparation of 1-amino-3-thienoisoxazolylphenoxy-2-propanols as dopamine D4 antagonists
INVENTOR(S): Fink, David M.; Freed, Brian S.; Hrib, Nicholas J.; Kosley, Raymond W., Jr.; Lee, George E.; Merriman, Gregory H.; Rauckman, Barbara S.
PATENT ASSIGNEE(S): Aventis Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 157 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001019833	A1	20010322	WO 2000-US24962	20000913
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
BR 2000014515	A	20020625	BR 2000-14515	20000913
EP 1216250	A1	20020626	EP 2000-964969	20000913
EP 1216250	B1	20031119		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
EE 200200135	A	20030415	EE 2002-135	20000913
AT 254621	E	20031215	AT 2000-964969	20000913
PT 1216250	T	20040430	PT 2000-964969	20000913
ES 2209995	T3	20040701	ES 2000-964969	20000913
TW 530060	B	20030501	TW 2000-89118850	20000914
NO 2002001251	A	20020510	NO 2002-1251	20020313
ZA 2002001762	A	20030602	ZA 2002-1762	20020321
PRIORITY APPLN. INFO.:			US 1999-396081	A1 19990914
			WO 2000-US24962	W 20000913

OTHER SOURCE(S): MARPAT 134:237472

AB RZOCH2CR1R2CH2NR3R4 [I; R = e.g., thieno[2,3-d]isoxazol-3-yl; R1 = OH or alkoxy; R2,R4 = H or alkyl; R3 = CH2R5, CH2CH(OH)R5, indanyl, etc.; R5 = cyclohex(en)yl, (hetero)aryl, etc.; Z = phenylene] were prepared Thus, 3-bromothiophene was acylated by 3-(MeO)C6H4COCl and the oximated product cyclized to give, after O-demethylation, 3-RC6H4OH [R = thieno[2,3-d]isoxazol-3-yl] which was etherified by (R)-glycidyl tosylate and the product aminated by PhCHMeNH2 to give (R)-3-RC6H4OCH2CH(OH)CH2NMeCH2Ph (R as above). Data for biol. activity of I were given.

IT **330650-04-9P 330650-17-4P 330650-18-5P**
330650-19-6P 330650-20-9P 330650-21-0P
330650-22-1P 330650-23-2P 330650-24-3P
330650-25-4P 330650-26-5P 330650-27-6P
330650-28-7P 330650-29-8P 330650-30-1P
330650-31-2P 330650-32-3P 330650-33-4P
330650-34-5P 330650-35-6P 330650-36-7P
330650-37-8P 330650-38-9P 330650-39-0P
330650-51-6P 330650-52-7P 330650-53-8P
330650-56-1P 330650-57-2P 330650-59-4P
330650-60-7P 330650-61-8P 330650-67-4P
330650-68-5P 330650-69-6P 330650-70-9P
330650-71-0P 330650-72-1P 330650-73-2P
330650-74-3P 330650-75-4P 330650-76-5P
330650-77-6P 330650-78-7P 330650-79-8P
330650-82-3P 330650-83-4P 330650-84-5P
330650-85-6P 330650-86-7P 330650-87-8P
330650-88-9P 330650-89-0P 330650-90-3P
330650-91-4P 330650-96-9P 330650-98-1P
330650-99-2P 330651-04-2P 330651-05-3P
330651-06-4P 330651-07-5P 330651-08-6P
330651-09-7P 330651-10-0P 330651-11-1P
330651-18-8P 330651-21-3P 330651-22-4P
330651-23-5P 330672-14-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 1-amino-3-thienoisoxazolylphenoxy-2-propanols as dopamine D4 antagonists)

RN 330650-04-9 CAPLUS
CN 2-Propanol, 1-[methyl(phenylmethyl)amino]-3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)-, monohydrochloride, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



● HCl

RN 330650-17-4 CAPLUS
CN 2-Propanol, 1-[(2-pyridinylmethyl)amino]-3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 330650-18-5 CAPLUS
CN 2-Propanol, 1-[(1-naphthalenylmethyl)amino]-3-(4-thieno[2,3-d]isoxazol-3-ylphenoxy)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 330650-19-6 CAPLUS

CN 2-Propanol, 1-(4-thieno[2,3-d]isoxazol-3-ylphenoxy)-3-[(3-thienylmethyl)amino]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 330650-20-9 CAPLUS
CN 2-Propanol, 1-[(2-furanylmethyl)amino]-3-(4-thieno[2,3-d]isoxazol-3-ylphenoxy)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 330650-21-0 CAPLUS
CN 2-Propanol, 1-(4-thieno[2,3-d]isoxazol-3-ylphenoxy)-3-[(2-thienylmethyl)amino]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 330650-22-1 CAPLUS
CN 2-Propanol, 2-methyl-1-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)-3-[(2-thienylmethyl)amino]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 330650-23-2 CAPLUS
CN 2-Propanol, 2-methyl-1-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)-3-[(2-thienylmethyl)amino]-, (2R)-, (2Z)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 330650-22-1
CMF C20 H20 N2 O3 S2

Absolute stereochemistry.



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 330650-24-3 CAPLUS
CN 2-Propanol, 1-[[(4-methoxyphenyl)methyl]amino]-2-methyl-3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 330650-25-4 CAPLUS
CN 2-Propanol, 1-[[(2-methoxyphenyl)methyl]amino]-2-methyl-3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 330650-26-5 CAPLUS
CN 2-Propanol, 1-[[(4-chlorophenyl)methyl]amino]-2-methyl-3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 330650-27-6 CAPLUS
CN 2-Propanol, 1-[[(4-fluorophenyl)methyl]amino]-2-methyl-3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 330650-28-7 CAPLUS

CN 2-Propanol, 1-[[(2-fluorophenyl)methyl]amino]-2-methyl-3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 330650-29-8 CAPLUS
CN 2-Propanol, 1-[(2-furanylmethyl)amino]-2-methyl-3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 330650-30-1 CAPLUS
CN 2-Propanol, 2-methyl-1-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)-3-[[[4-(trifluoromethyl)phenyl]methyl]amino]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 330650-31-2 CAPLUS
CN 2-Propanol, 2-methyl-1-[[(1R)-1-phenylethyl]amino]-3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 330650-32-3 CAPLUS
CN 2-Propanol, 2-methyl-1-[[(1S)-1-phenylethyl]amino]-3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 330650-33-4 CAPLUS
CN 2-Propanol, 2-methyl-1-[(1-naphthalenylmethyl)amino]-3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 330650-34-5 CAPLUS
CN 2-Propanol, 2-methyl-1-[(4-pyridinylmethyl)amino]-3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 330650-35-6 CAPLUS
CN 2-Propanol, 2-methyl-1-[(3-pyridinylmethyl)amino]-3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 330650-36-7 CAPLUS
CN 2-Propanol, 2-methyl-1-[(2-pyridinylmethyl)amino]-3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 330650-37-8 CAPLUS
CN 2-Propanol, 1-[(2-furanylmethyl)amino]-3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)-, monohydrochloride, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 330650-38-9 CAPLUS
CN 2-Propanol, 1-[(3-pyridinylmethyl)amino]-3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)-, dihydrochloride, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 330650-39-0 CAPLUS
CN Benzenemethanol, α-[[[(2R)-2-hydroxy-2-methyl-3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)propyl]amino]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 330650-51-6 CAPLUS
CN Benzenemethanamine, N-[(2R)-2-methoxy-3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)propyl]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 330650-52-7 CAPLUS
CN Benzenemethanamine, N-[(2R)-2-methoxy-3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)propyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 330650-53-8 CAPLUS
CN Benzenemethanamine, N-[(2R)-2-methoxy-3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)propyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 330650-56-1 CAPLUS
CN 2-Propanol, 1-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)-3-[(2-thienylmethyl)amino]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 330650-57-2 CAPLUS
CN 2-Propanol, 1-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)-3-[(2-thienylmethyl)amino]-, (2R)-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 330650-56-1
CMF C19 H18 N2 O3 S2

Absolute stereochemistry.



CM 2

CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.



RN 330650-59-4 CAPLUS
CN 2-Propanol, 1-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)-3-[(3-thienylmethyl)amino]-, monohydrochloride, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 330650-60-7 CAPLUS
CN 2-Propanol, 1-[(1-naphthalenylmethyl)amino]-3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)-, monohydrochloride, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 330650-61-8 CAPLUS
CN 2-Propanol, 1-[(1-naphthalenylmethyl)amino]-3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 330650-67-4 CAPLUS
CN 2-Propanol, 2-methyl-1-[(phenylmethyl)amino]-3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 330650-68-5 CAPLUS
CN 2-Propanol, 2-methyl-1-[(phenylmethyl)amino]-3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)-, (2S)-, (2Z)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 330650-67-4
CMF C22 H22 N2 O3 S

Absolute stereochemistry.



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 330650-69-6 CAPLUS
CN 2-Propanol, 2-methyl-1-[(phenylmethyl)amino]-3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 330650-70-9 CAPLUS
CN 2-Propanol, 2-methyl-1-[(phenylmethyl)amino]-3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)-, (2R)-, (2Z)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 330650-69-6
CMF C22 H22 N2 O3 S

Absolute stereochemistry. Rotation (-).



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 330650-71-0 CAPLUS
CN 2-Propanol, 2-methyl-1-[methyl(phenylmethyl)amino]-3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)-, monohydrochloride, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 330650-72-1 CAPLUS
CN 2-Propanol, 1-[[(4-fluorophenyl)methyl]amino]-2-methyl-3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 330650-73-2 CAPLUS
CN 2-Propanol, 1-[[(2-fluorophenyl)methyl]amino]-2-methyl-3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 330650-74-3 CAPLUS
CN 2-Propanol, 1-[[(3-fluorophenyl)methyl]amino]-2-methyl-3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 330650-75-4 CAPLUS
CN 2-Propanol, 1-[[(4-chlorophenyl)methyl]amino]-2-methyl-3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 330650-76-5 CAPLUS
CN 2-Propanol, 1-[[(2-chlorophenyl)methyl]amino]-2-methyl-3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 330650-77-6 CAPLUS
CN 2-Propanol, 1-[[(3,4-dichlorophenyl)methyl]amino]-2-methyl-3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 330650-78-7 CAPLUS
CN 2-Propanol, 2-methyl-1-[[(1R)-1-phenylethyl]amino]-3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 330650-79-8 CAPLUS
CN 2-Propanol, 2-methyl-1-[[(1S)-1-phenylethyl]amino]-3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 330650-82-3 CAPLUS
CN 2-Propanol, 2-methyl-1-[(1-naphthalenylmethyl)amino]-3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 330650-83-4 CAPLUS
CN 2-Propanol, 2-methyl-1-[[(4-methylphenyl)methyl]amino]-3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 330650-84-5 CAPLUS
CN 2-Propanol, 1-[[(4-methoxyphenyl)methyl]amino]-2-methyl-3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 330650-85-6 CAPLUS
CN 2-Propanol, 1-[[(2-methoxyphenyl)methyl]amino]-2-methyl-3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 330650-86-7 CAPLUS
CN 2-Propanol, 1-[(2-furanylmethyl)amino]-2-methyl-3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 330650-87-8 CAPLUS

CN 2-Propanol, 2-methyl-1-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)-3-[(2-thienylmethyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 330650-88-9 CAPLUS
CN 2-Propanol, 2-methyl-1-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)-3-[(3-thienylmethyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 330650-89-0 CAPLUS
CN 2-Propanol, 2-methyl-1-[(3-pyridinylmethyl)amino]-3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 330650-90-3 CAPLUS
CN 2-Propanol, 2-methyl-1-[(2-pyridinylmethyl)amino]-3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 330650-91-4 CAPLUS
CN 2-Propanol, 2-methyl-1-[methyl(phenylmethyl)amino]-3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 330650-96-9 CAPLUS
CN 2-Propanol, 1-[(1H-benzimidazol-2-ylmethyl)amino]-3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 330650-98-1 CAPLUS
CN 2-Propanol, 1-[(4-pyridinylmethyl)amino]-3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 330650-99-2 CAPLUS

CN 2-Propanol, 1-[(1,2,3,4-tetrahydro-1-naphthalenyl)amino]-3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 330651-04-2 CAPLUS
CN 2-Propanol, 1-[(2,3-dihydro-1H-inden-2-yl)amino]-3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)-, monohydrochloride, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 330651-05-3 CAPLUS
CN 2-Propanol, 1-[(2,3-dihydro-1H-inden-2-yl)amino]-3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 330651-06-4 CAPLUS
CN 2-Propanol, 1-[(cyclohexylmethyl)amino]-3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 330651-07-5 CAPLUS
CN 2-Propanol, 1-[(2,3-dihydro-1H-inden-1-yl)amino]-3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 330651-08-6 CAPLUS
CN 2-Propanol, 1-[[(4-fluorophenyl)methyl]amino]-2-methyl-3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)-, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 330651-09-7 CAPLUS
CN 2-Propanol, 1-[[(3,4-dichlorophenyl)methyl]amino]-2-methyl-3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)-, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 330651-10-0 CAPLUS
CN 2-Propanol, 1-[[(3,4-difluorophenyl)methyl]amino]-2-methyl-3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)-, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 330651-11-1 CAPLUS
CN 2-Propanol, 1-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)-3-(tricyclo[3.3.1.13,7]dec-1-ylamino)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 330651-18-8 CAPLUS
CN 2-Propanol, 1-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)-3-[(3-thienylmethyl)amino]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 330651-21-3 CAPLUS
CN Benzenemethanol, α-[[[(2R)-2-hydroxy-3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)propyl]amino]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 330651-22-4 CAPLUS
CN Benzenemethanamine, N-[(2R)-2-methoxy-3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 330651-23-5 CAPLUS
CN 2-Propanol, 1-[[(3,4-difluorophenyl)methyl]amino]-2-methyl-3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 330672-14-5 CAPLUS
CN 2-Propanol, 1-[methyl(phenylmethyl)amino]-3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT **330651-36-0P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 1-amino-3-thienoisoxazolylphenoxy-2-propanols as dopamine D4 antagonists)
RN 330651-36-0 CAPLUS
CN 2-Propanol, 1-[(phenylmethyl)amino]-3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2001:208281 CAPLUS
DOCUMENT NUMBER: 134:252333
TITLE: Preparation of N-(aralkyl)(thienoisoxazolylphenoxy)alkanamines and analogs as dopamine D4 antagonists
INVENTOR(S): Lee, George E.; Ayers, Timothy A.; Jurcak, John G.
PATENT ASSIGNEE(S): Aventis Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 108 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001019832	A2	20010322	WO 2000-US24949	20000913
WO 2001019832	A3	20011004		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,

CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,
YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,
CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

EP 1216249	A2	20020626	EP 2000-964967	20000913
EP 1216249	B1	20031119		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
BR 2000014513	A	20020702	BR 2000-14513	20000913
EE 200200133	A	20030415	EE 2002-133	20000913
AT 254620	E	20031215	AT 2000-964967	20000913
PT 1216249	T	20040430	PT 2000-964967	20000913
ES 2206305	T3	20040516	ES 2000-964967	20000913
ZA 2002001760	A	20030602	ZA 2002-1760	20020301
NO 2002001249	A	20020510	NO 2002-1249	20020313
PRIORITY APPLN. INFO.:			US 1999-396156 A1	19990914
			WO 2000-US24949 W	20000913

OTHER SOURCE(S): MARPAT 134:252333

AB ROZR3 [R3 = thieno[2,3-d]isoxazol-3-yl throughout][I; R = Z1NR1R2 or 1-benzyl-3-pyrrolidinyl; R1 = CH2R4, CH2CH(OH)R4, CHMeR4, indanyl, etc.; R2 = H or alkyl; NR1R2 = heterocyclyl; R4 = cyclohexenyl, (hetero)aryl, etc.; Z = phenylene; Z1 = alkylene] were prepared Thus, 3-bromothiophene was acylated by 3-(MeO)C6H4COCl and the oximated product cyclized to give, after O-demethylation, 3-R3C6H4OH which was etherified by 3-FC6H4CH2NHCOCH2Cl (preparation given) and the product reduced to give 3-R3C6H4OCH2CH2NHCH2C6H4F-3. Data for biol. activity of I were given.

IT **330678-80-3P 330678-81-4P 330678-82-5P**
330678-83-6P 330678-84-7P 330678-85-8P
330678-86-9P 330678-87-0P 330678-88-1P
330678-89-2P 330678-94-9P 330678-95-0P
330679-25-9P 330679-26-0P 330679-27-1P
330679-28-2P 330679-29-3P 330679-30-6P
330679-33-9P 330679-35-1P 330679-36-2P
330679-37-3P 330679-38-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-(aralkyl)(thienoisoxazolylphenoxy)alkanamines and analogs as dopamine D4 antagonists)

RN 330678-80-3 CAPLUS

CN Benzenemethanamine, 3-fluoro-N-[3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)propyl]- (9CI) (CA INDEX NAME)



RN 330678-81-4 CAPLUS

CN Benzenemethanamine, N-[3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)propyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 330678-82-5 CAPLUS
CN Benzenemethanamine, N-[3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)propyl]- (9CI) (CA INDEX NAME)



RN 330678-83-6 CAPLUS
CN Benzenemethanamine, 4-fluoro-N-[3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)propyl]- (9CI) (CA INDEX NAME)



RN 330678-84-7 CAPLUS
CN Benzenemethanamine, 4-chloro-N-[3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)propyl]- (9CI) (CA INDEX NAME)



RN 330678-85-8 CAPLUS
CN Benzenemethanamine, 4-methoxy-N-[3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)propyl]- (9CI) (CA INDEX NAME)



RN 330678-86-9 CAPLUS
CN 2-Thiophenemethanamine, N-[3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)propyl]- (9CI) (CA INDEX NAME)



RN 330678-87-0 CAPLUS
CN 3-Thiophenemethanamine, N-[3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)propyl]-
(9CI) (CA INDEX NAME)



RN 330678-88-1 CAPLUS
CN 3-Pyridinemethanamine, N-[3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)propyl]-
(9CI) (CA INDEX NAME)



RN 330678-89-2 CAPLUS
CN Benzenemethanol, α-[[[3-(3-thieno[2,3-d]isoxazol-3-
ylphenoxy)propyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 330678-94-9 CAPLUS
CN Benzenesulfonamide, 4-[[[3-(3-thieno[2,3-d]isoxazol-3-
ylphenoxy)propyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 330678-95-0 CAPLUS
CN Benzenesulfonamide, 4-[2-[[3-(3-thieno[2,3-d]isoxazol-3-

ylphenoxy)propyl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 330679-25-9 CAPLUS
CN Benzenemethanamine, 4-methyl-N-[3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)propyl]- (9CI) (CA INDEX NAME)



RN 330679-26-0 CAPLUS
CN Benzenemethanamine, 2-chloro-N-[3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)propyl]- (9CI) (CA INDEX NAME)



RN 330679-27-1 CAPLUS
CN Benzenemethanamine, 3-methoxy-N-[3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)propyl]- (9CI) (CA INDEX NAME)



RN 330679-28-2 CAPLUS
CN Benzenemethanamine, 3,4-difluoro-N-[3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)propyl]- (9CI) (CA INDEX NAME)



RN 330679-29-3 CAPLUS
CN 1H-Inden-1-amine, 2,3-dihydro-N-[3-(3-thieno[2,3-d]isoxazol-3-

ylphenoxy)propyl]- (9CI) (CA INDEX NAME)



RN 330679-30-6 CAPLUS
CN 1H-Inden-2-amine, 2,3-dihydro-N-[3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)propyl]- (9CI) (CA INDEX NAME)



RN 330679-33-9 CAPLUS
CN Tricyclo[3.3.1.13,7]decan-1-amine, N-[3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)propyl]- (9CI) (CA INDEX NAME)



RN 330679-35-1 CAPLUS
CN Benzenemethanamine, 2,4-difluoro-N-[3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)propyl]- (9CI) (CA INDEX NAME)



RN 330679-36-2 CAPLUS
CN Benzenemethanamine, 2,6-difluoro-N-[3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)propyl]- (9CI) (CA INDEX NAME)



RN 330679-37-3 CAPLUS
CN Benzenemethanamine, N-[3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)propyl]-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 330679-38-4 CAPLUS
CN Benzenemethanamine, N-[3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)propyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1987:598314 CAPLUS
DOCUMENT NUMBER: 107:198314
TITLE: Preparation of [(3-aminopropoxy)phenyl]thienoisoxazoles and- pyrazoles for treatment of hypertension and glaucoma
INVENTOR(S): Ong, Helen Hu; Yasenchak, Christine Mary
PATENT ASSIGNEE(S): Hoechst-Roussel Pharmaceuticals, Inc., USA
SOURCE: Eur. Pat. Appl., 73 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 221414	A1	19870513	EP 1986-114314	19861016
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
US 4728651	A	19880301	US 1985-791019	19851024
DK 8605079	A	19870425	DK 1986-5079	19861023
AU 8664337	A1	19870430	AU 1986-64337	19861023
JP 62103086	A2	19870513	JP 1986-250937	19861023
ZA 8608065	A	19870624	ZA 1986-8065	19861023
HU 45061	A2	19880530	HU 1986-4456	19861023
HU 198058	B	19890728		
US 4769472	A	19880906	US 1987-125108	19871125

PRIORITY APPLN. INFO.: US 1985-791019 19851024
OTHER SOURCE(S): CASREACT 107:198314
GI



I



II

AB The title compds. [I; X = O, NR; R = H, alkyl; R1 = H; R2 = alkyl, arylalkyl, aryloxyalkyl, indolylalkyl, benzodioxarylalkyl, or NR1R2 = (arylalkyl)piperazinyl] were prepared as antihypertensives and for reduction of intraocular pressure. 3-[(2-Epoxymethoxy)phenyl]-1-methyl-1H-thieno[3,2-c]pyrazole 3 g was refluxed with Me3CNH2 in EtOH for 5 h to give 2.5 g of [(aminopropoxy)phenyl]thienopyrazole derivative (II).2HCl. II reduced outflow pressure by 51% when administered to an eye as a 2% solution

IT **110894-42-3P 110894-43-4P 110894-44-5P**
110894-45-6P 110894-46-7P 110894-47-8P
110894-48-9P 110894-49-0P 110894-50-3P
110894-51-4P 110894-52-5P 110894-53-6P
110894-54-7P 110894-55-8P 110894-58-1P
110894-59-2P 110894-60-5P 110894-61-6P
110894-62-7P 110894-63-8P 110894-64-9P
110894-65-0P 110894-66-1P 110894-67-2P
110894-68-3P 110894-69-4P 110894-70-7P
110894-71-8P 110894-72-9P 110894-73-0P
110894-74-1P 110894-75-2P 110894-76-3P
110894-77-4P 110916-52-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, for treatment of hypertension and glaucoma)

RN 110894-42-3 CAPLUS
CN 2-Propanol, 1-[(1,1-dimethylethyl)amino]-3-(2-thieno[2,3-d]isoxazol-3-ylphenoxy)- (9CI) (CA INDEX NAME)



RN 110894-43-4 CAPLUS
CN 2-Propanol, 1-[(1-methylethyl)amino]-3-(2-thieno[2,3-d]isoxazol-3-ylphenoxy)- (9CI) (CA INDEX NAME)



RN 110894-44-5 CAPLUS
CN 2-Propanol, 1-[[2-(3,4-dimethoxyphenyl)ethyl]amino]-3-(2-thieno[2,3-d]isoxazol-3-ylphenoxy)- (9CI) (CA INDEX NAME)



RN 110894-45-6 CAPLUS
CN 2-Propanol, 1-[(1,1-dimethylethyl)amino]-3-[2-(1-methyl-1H-thieno[3,2-c]pyrazol-3-yl)phenoxy]- (9CI) (CA INDEX NAME)



RN 110894-46-7 CAPLUS
CN 2-Propanol, 1-[[2-(3,4-dimethoxyphenyl)ethyl]amino]-3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)- (9CI) (CA INDEX NAME)



RN 110894-47-8 CAPLUS

CN 2-Propanol, 1-[(1-methyl-3-phenylpropyl)amino]-3-[2-(1-methyl-1H-thieno[3,2-c]pyrazol-3-yl)phenoxy]- (9CI) (CA INDEX NAME)



RN 110894-48-9 CAPLUS
CN 2-Propanol, 1-[(1-methyl-2-phenoxyethyl)amino]-3-[2-(1-methyl-1H-thieno[3,2-c]pyrazol-3-yl)phenoxy]- (9CI) (CA INDEX NAME)



RN 110894-49-0 CAPLUS
CN 2-Propanol, 1-[(1-methylethyl)amino]-3-(2-thieno[2,3-d]isoxazol-3-ylphenoxy)-, (2Z)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 110894-43-4
CMF C17 H20 N2 O3 S



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 110894-50-3 CAPLUS
CN 2-Propanol, 1-[(1,1-dimethylethyl)amino]-3-(2-thieno[2,3-d]isoxazol-3-ylphenoxy)-, (2Z)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 110894-42-3
CMF C18 H22 N2 O3 S



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 110894-51-4 CAPLUS
CN 2-Propanol, 1-[(1-methyl-3-phenylpropyl)amino]-3-(2-thieno[2,3-d]isoxazol-3-ylphenoxy)- (9CI) (CA INDEX NAME)



RN 110894-52-5 CAPLUS
CN 2-Propanol, 1-[[(2,3-dihydro-1,4-benzodioxin-2-yl)methyl]amino]-3-(2-

thieno[2,3-d]isoxazol-3-ylphenoxy)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 110894-53-6 CAPLUS
CN 2-Propanol, 1-[[2-(1H-indol-3-yl)ethyl]amino]-3-(2-thieno[2,3-d]isoxazol-3-ylphenoxy)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 110894-54-7 CAPLUS
CN 2-Propanol, 1-[(1-methylethyl)amino]-3-[2-(1-methyl-1H-thieno[3,2-c]pyrazol-3-yl)phenoxy]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 110894-55-8 CAPLUS
CN 2-Propanol, 1-[(1,1-dimethylethyl)amino]-3-[2-(1-methyl-1H-thieno[3,2-c]pyrazol-3-yl)phenoxy]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 110894-58-1 CAPLUS
CN 2-Propanol, 1-[(1-methyl-3-phenylpropyl)amino]-3-[2-(1-methyl-1H-thieno[3,2-c]pyrazol-3-yl)phenoxy]-, ethanedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 110894-47-8
CMF C25 H29 N3 O2 S



CM 2

CRN 144-62-7
CMF C2 H2 O4



RN 110894-59-2 CAPLUS
CN 2-Propanol, 1-[(1-methylethyl)amino]-3-(3-thieno[2,3-b]isoxazol-3-ylphenoxy)- (9CI) (CA INDEX NAME)



RN 110894-60-5 CAPLUS
CN 2-Propanol, 1-[(1-methylethyl)amino]-3-(3-thieno[2,3-b]isoxazol-3-ylphenoxy)-, (2Z)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 110894-59-2
CMF C17 H20 N2 O3 S



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 110894-61-6 CAPLUS
CN 2-Propanol, 1-[(1,1-dimethylethyl)amino]-3-(3-thieno[2,3-d]isoxazol-4-ylphenoxy)- (9CI) (CA INDEX NAME)



RN 110894-62-7 CAPLUS
CN 2-Propanol, 1-[(1,1-dimethylethyl)amino]-3-(3-thieno[2,3-d]isoxazol-4-ylphenoxy)-, (2Z)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 110894-61-6
CMF C18 H22 N2 O3 S



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 110894-63-8 CAPLUS
CN 2-Propanol, 1-[[2-(3,4-dimethoxyphenyl)ethyl]amino]-3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 110894-64-9 CAPLUS
CN 2-Propanol, 1-[(1-methylethyl)amino]-3-(4-thieno[2,3-d]isoxazol-3-ylphenoxy)- (9CI) (CA INDEX NAME)



RN 110894-65-0 CAPLUS
CN 2-Propanol, 1-[(1-methylethyl)amino]-3-(4-thieno[2,3-d]isoxazol-3-ylphenoxy)-, (2Z)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 110894-64-9
CMF C17 H20 N2 O3 S



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 110894-66-1 CAPLUS
CN 2-Propanol, 1-[(1,1-dimethylethyl)amino]-3-(4-thieno[2,3-d]isoxazol-3-ylphenoxy)- (9CI) (CA INDEX NAME)



RN 110894-67-2 CAPLUS
CN 2-Propanol, 1-[[2-(3,4-dimethoxyphenyl)ethyl]amino]-3-[2-(1H-thieno[3,2-c]pyrazol-3-yl)phenoxy]- (9CI) (CA INDEX NAME)



RN 110894-68-3 CAPLUS
CN 2-Propanol, 1-[[2-(3,4-dimethoxyphenyl)ethyl]amino]-3-[2-(1H-thieno[3,2-c]pyrazol-3-yl)phenoxy]-, (2E)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 110894-67-2
CMF C24 H27 N3 O4 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 110894-69-4 CAPLUS
CN 2-Propanol, 1-[(1-methyl-2-phenoxyethyl)amino]-3-[2-(1H-thieno[3,2-c]pyrazol-3-yl)phenoxy]- (9CI) (CA INDEX NAME)



RN 110894-70-7 CAPLUS
CN 2-Propanol, 1-[(1-methyl-2-phenoxyethyl)amino]-3-[2-(1H-thieno[3,2-c]pyrazol-3-yl)phenoxy]-, (2Z)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 110894-69-4
CMF C23 H25 N3 O3 S



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 110894-71-8 CAPLUS
CN 2-Propanol, 1-[[2-(2-methoxyphenoxy)ethyl]amino]-3-[2-(1-methyl-1H-thieno[3,2-c]pyrazol-3-yl)phenoxy]- (9CI) (CA INDEX NAME)



RN 110894-72-9 CAPLUS
CN 2-Propanol, 1-[[2-(2-methoxyphenoxy)ethyl]amino]-3-[2-(1-methyl-1H-thieno[3,2-c]pyrazol-3-yl)phenoxy]-, (2E)-2-butenedioate (2:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 110894-71-8
CMF C24 H27 N3 O4 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 110894-73-0 CAPLUS
CN 2-Propanol, 1-[[2-(2-methoxyphenoxy)-1-methylethyl]amino]-3-[2-(1-methyl-1H-thieno[3,2-c]pyrazol-3-yl)phenoxy]- (9CI) (CA INDEX NAME)



RN 110894-74-1 CAPLUS
CN 2-Propanol, 1-[[2-(2-methoxyphenoxy)-1-methylethyl]amino]-3-[2-(1-methyl-1H-thieno[3,2-c]pyrazol-3-yl)phenoxy]-, (2Z)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 110894-73-0
CMF C25 H29 N3 O4 S



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 110894-75-2 CAPLUS
CN 2-Propanol, 1-[(1-methylethyl)amino]-3-[3-(1-methyl-1H-thieno[3,2-c]pyrazol-3-yl)phenoxy]- (9CI) (CA INDEX NAME)



RN 110894-76-3 CAPLUS
CN 2-Propanol, 1-[[(2,3-dihydro-1,4-benzodioxin-2-yl)methyl]amino]-3-(2-thieno[2,3-d]isoxazol-3-ylphenoxy)- (9CI) (CA INDEX NAME)



RN 110894-77-4 CAPLUS
CN 2-Propanol, 1-[(1-methylethyl)amino]-3-[2-(1-methyl-1H-thieno[3,2-c]pyrazol-3-yl)phenoxy]- (9CI) (CA INDEX NAME)



RN 110916-52-4 CAPLUS
CN 2-Propanol, 1-[[2-(1H-indol-3-yl)ethyl]amino]-3-(2-thieno[2,3-d]isoxazol-3-ylphenoxy)- (9CI) (CA INDEX NAME)



=> FIL REGISTRY

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	19.56	175.19

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-2.10	-2.10

FILE 'REGISTRY' ENTERED AT 09:02:09 ON 21 OCT 2004

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 20 OCT 2004 HIGHEST RN 766487-31-4
DICTIONARY FILE UPDATES: 20 OCT 2004 HIGHEST RN 766487-31-4

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading C:\Program Files\Stnexp\Queries\10088250a.str



chain nodes :
16 17 18 19 20 23 24
ring nodes :
1 2 3 4 5 6 7 8 10 11 12 13 14 15
chain bonds :
2-14 16-17 17-18 18-19 19-20 20-23 23-24
ring bonds :
1-6 1-3 2-5 2-3 4-5 4-8 5-6 6-7 7-8 10-11 10-15 11-12 12-13 13-14
14-15
exact/norm bonds :
1-6 1-3 2-5 2-3 2-14 4-5 4-8 5-6 6-7 7-8 16-17 17-18 18-19 19-20
20-23 23-24
normalized bonds :
10-11 10-15 11-12 12-13 13-14 14-15
isolated ring systems :
containing 1 : 10 :

G1:O,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 10:Atom 11:Atom
12:Atom 13:Atom 14:Atom 15:Atom 16:CLASS 17:CLASS 18:CLASS 19:CLASS
20:CLASS 22:CLASS 23:CLASS 24:Atom

L5 STRUCTURE UPLOADED

=> d l5
L5 HAS NO ANSWERS
L5 STR



G1 O,N

Structure attributes must be viewed using STN Express query preparation.

=> s l5
SAMPLE SEARCH INITIATED 09:02:38 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 5 TO ITERATE

100.0% PROCESSED 5 ITERATIONS 3 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 5 TO 234
PROJECTED ANSWERS: 3 TO 163

L6 3 SEA SSS SAM L5

=> s l5 sss full
FULL SEARCH INITIATED 09:02:45 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 134 TO ITERATE

100.0% PROCESSED 134 ITERATIONS 89 ANSWERS
SEARCH TIME: 00.00.01

L7 89 SEA SSS FUL L5

=> FIL CAPLUS

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	157.94	333.13

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-2.10

FILE 'CAPLUS' ENTERED AT 09:06:32 ON 21 OCT 2004

FILE COVERS 1907 - 21 Oct 2004 VOL 141 ISS 17
FILE LAST UPDATED: 20 Oct 2004 (20041020/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l7
L8 3 L7

=> d his

(FILE 'HOME' ENTERED AT 08:54:27 ON 21 OCT 2004)

FILE 'REGISTRY' ENTERED AT 08:54:39 ON 21 OCT 2004
L1 STRUCTURE UPLOADED
L2 5 S L1
L3 131 S L1 SSS FULL

FILE 'CAPLUS' ENTERED AT 08:55:13 ON 21 OCT 2004
L4 3 S L3

FILE 'REGISTRY' ENTERED AT 09:02:09 ON 21 OCT 2004
L5 STRUCTURE UPLOADED
L6 3 S L5
L7 89 S L5 SSS FULL

FILE 'CAPLUS' ENTERED AT 09:06:32 ON 21 OCT 2004
L8 3 S L7

=> s l4 and py<=1999
19742471 PY<=1999
L9 1 L4 AND PY<=1999

=> s l8 and py<=1999
19742471 PY<=1999
L10 1 L8 AND PY<=1999

=> d l7 ibib abs hitstr tot
YOU HAVE REQUESTED DATA FROM FILE 'REGISTRY' - CONTINUE? (Y)/N:end

=> d l8 ibib abs hitstr tot

L8 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2001:208282 CAPLUS
DOCUMENT NUMBER: 134:237472
TITLE: Preparation of 1-amino-3-thienoisoxazolylphenoxy-2-propanols as dopamine D4 antagonists

INVENTOR(S): Fink, David M.; Freed, Brian S.; Hrib, Nicholas J.; Kosley, Raymond W., Jr.; Lee, George E.; Merriman, Gregory H.; Rauckman, Barbara S.
PATENT ASSIGNEE(S): Aventis Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 157 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001019833	A1	20010322	WO 2000-US24962	20000913
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
BR 2000014515	A	20020625	BR 2000-14515	20000913
EP 1216250	A1	20020626	EP 2000-964969	20000913
EP 1216250	B1	20031119		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
EE 200200135	A	20030415	EE 2002-135	20000913
AT 254621	E	20031215	AT 2000-964969	20000913
PT 1216250	T	20040430	PT 2000-964969	20000913
ES 2209995	T3	20040701	ES 2000-964969	20000913
TW 530060	B	20030501	TW 2000-89118850	20000914
NO 2002001251	A	20020510	NO 2002-1251	20020313
ZA 2002001762	A	20030602	ZA 2002-1762	20020321
PRIORITY APPLN. INFO.:			US 1999-396081	A1 19990914
			WO 2000-US24962	W 20000913

OTHER SOURCE(S): MARPAT 134:237472

AB RZOCH2CR1R2CH2NR3R4 [I; R = e.g., thieno[2,3-d]isoxazol-3-yl; R1 = OH or alkoxy; R2,R4 = H or alkyl; R3 = CH2R5, CH2CH(OH)R5, indanyl, etc.; R5 = cyclohex(en)yl, (hetero)aryl, etc.; Z = phenylene] were prepared Thus, 3-bromothiophene was acylated by 3-(MeO)C6H4COCl and the oximated product cyclized to give, after O-demethylation, 3-RC6H4OH [R = thieno[2,3-d]isoxazol-3-yl] which was etherified by (R)-glycidyl tosylate and the product aminated by PhCHMeNH2 to give (R)-3-RC6H4OCH2CH(OH)CH2NMeCH2Ph (R as above). Data for biol. activity of I were given.

IT **330650-04-9P 330650-17-4P 330650-18-5P**
330650-19-6P 330650-20-9P 330650-21-0P
330650-22-1P 330650-23-2P 330650-24-3P
330650-25-4P 330650-26-5P 330650-27-6P
330650-28-7P 330650-29-8P 330650-30-1P
330650-33-4P 330650-34-5P 330650-35-6P
330650-36-7P 330650-37-8P 330650-38-9P
330650-51-6P 330650-52-7P 330650-53-8P
330650-56-1P 330650-57-2P 330650-59-4P
330650-60-7P 330650-61-8P 330650-67-4P
330650-68-5P 330650-69-6P 330650-70-9P
330650-71-0P 330650-72-1P 330650-73-2P
330650-74-3P 330650-75-4P 330650-76-5P

330650-77-6P 330650-82-3P 330650-83-4P
330650-84-5P 330650-85-6P 330650-86-7P
330650-87-8P 330650-88-9P 330650-89-0P
330650-90-3P 330650-91-4P 330650-96-9P
330650-98-1P 330651-06-4P 330651-08-6P
330651-09-7P 330651-10-0P 330651-18-8P
330651-22-4P 330651-23-5P 330672-14-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 1-amino-3-thienoisoxazolylphenoxy-2-propanols as dopamine D4 antagonists)

RN 330650-04-9 CAPLUS
CN 2-Propanol, 1-[methyl(phenylmethyl)amino]-3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)-, monohydrochloride, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



● HCl

RN 330650-17-4 CAPLUS
CN 2-Propanol, 1-[(2-pyridinylmethyl)amino]-3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 330650-18-5 CAPLUS
CN 2-Propanol, 1-[(1-naphthalenylmethyl)amino]-3-(4-thieno[2,3-d]isoxazol-3-ylphenoxy)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 330650-19-6 CAPLUS
CN 2-Propanol, 1-(4-thieno[2,3-d]isoxazol-3-ylphenoxy)-3-[(3-thienylmethyl)amino]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 330650-20-9 CAPLUS
CN 2-Propanol, 1-[(2-furanylmethyl)amino]-3-(4-thieno[2,3-d]isoxazol-3-ylphenoxy)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 330650-21-0 CAPLUS
CN 2-Propanol, 1-(4-thieno[2,3-d]isoxazol-3-ylphenoxy)-3-[(2-thienylmethyl)amino]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 330650-22-1 CAPLUS
CN 2-Propanol, 2-methyl-1-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)-3-[(2-thienylmethyl)amino]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 330650-23-2 CAPLUS
CN 2-Propanol, 2-methyl-1-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)-3-[(2-thienylmethyl)amino]-, (2R)-, (2Z)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 330650-22-1
CMF C20 H20 N2 O3 S2

Absolute stereochemistry.



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 330650-24-3 CAPLUS
CN 2-Propanol, 1-[[(4-methoxyphenyl)methyl]amino]-2-methyl-3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 330650-25-4 CAPLUS
CN 2-Propanol, 1-[[(2-methoxyphenyl)methyl]amino]-2-methyl-3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 330650-26-5 CAPLUS
CN 2-Propanol, 1-[[(4-chlorophenyl)methyl]amino]-2-methyl-3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 330650-27-6 CAPLUS
CN 2-Propanol, 1-[[(4-fluorophenyl)methyl]amino]-2-methyl-3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 330650-28-7 CAPLUS
CN 2-Propanol, 1-[[(2-fluorophenyl)methyl]amino]-2-methyl-3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 330650-29-8 CAPLUS
CN 2-Propanol, 1-[(2-furanylmethyl)amino]-2-methyl-3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 330650-30-1 CAPLUS
CN 2-Propanol, 2-methyl-1-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)-3-[[[4-(trifluoromethyl)phenyl]methyl]amino]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 330650-33-4 CAPLUS

CN 2-Propanol, 2-methyl-1-[(1-naphthalenylmethyl)amino]-3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 330650-34-5 CAPLUS
CN 2-Propanol, 2-methyl-1-[(4-pyridinylmethyl)amino]-3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 330650-35-6 CAPLUS
CN 2-Propanol, 2-methyl-1-[(3-pyridinylmethyl)amino]-3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 330650-36-7 CAPLUS
CN 2-Propanol, 2-methyl-1-[(2-pyridinylmethyl)amino]-3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 330650-37-8 CAPLUS
CN 2-Propanol, 1-[(2-furanylmethyl)amino]-3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)-, monohydrochloride, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 330650-38-9 CAPLUS
CN 2-Propanol, 1-[(3-pyridinylmethyl)amino]-3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)-, dihydrochloride, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 330650-51-6 CAPLUS
CN Benzenemethanamine, N-[(2R)-2-methoxy-3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)propyl]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 330650-52-7 CAPLUS
CN Benzenemethanamine, N-[(2R)-2-methoxy-3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)propyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 330650-53-8 CAPLUS
CN Benzenemethanamine, N-[(2R)-2-methoxy-3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)propyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 330650-56-1 CAPLUS
CN 2-Propanol, 1-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)-3-[(2-thienylmethyl)amino]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 330650-57-2 CAPLUS
CN 2-Propanol, 1-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)-3-[(2-thienylmethyl)amino]-, (2R)-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 330650-56-1
CMF C19 H18 N2 O3 S2

Absolute stereochemistry.



CM 2

CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.



RN 330650-59-4 CAPLUS
CN 2-Propanol, 1-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)-3-[(3-thienylmethyl)amino]-, monohydrochloride, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 330650-60-7 CAPLUS
CN 2-Propanol, 1-[(1-naphthalenylmethyl)amino]-3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)-, monohydrochloride, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 330650-61-8 CAPLUS
CN 2-Propanol, 1-[(1-naphthalenylmethyl)amino]-3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 330650-67-4 CAPLUS
CN 2-Propanol, 2-methyl-1-[(phenylmethyl)amino]-3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 330650-68-5 CAPLUS
CN 2-Propanol, 2-methyl-1-[(phenylmethyl)amino]-3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)-, (2S)-, (2Z)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 330650-67-4
CMF C22 H22 N2 O3 S

Absolute stereochemistry.



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 330650-69-6 CAPLUS
CN 2-Propanol, 2-methyl-1-[(phenylmethyl)amino]-3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 330650-70-9 CAPLUS
CN 2-Propanol, 2-methyl-1-[(phenylmethyl)amino]-3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)-, (2R)-, (2Z)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 330650-69-6
CMF C22 H22 N2 O3 S

Absolute stereochemistry. Rotation (-).



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 330650-71-0 CAPLUS
CN 2-Propanol, 2-methyl-1-[methyl(phenylmethyl)amino]-3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)-, monohydrochloride, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 330650-72-1 CAPLUS
CN 2-Propanol, 1-[[(4-fluorophenyl)methyl]amino]-2-methyl-3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 330650-73-2 CAPLUS
CN 2-Propanol, 1-[[(2-fluorophenyl)methyl]amino]-2-methyl-3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 330650-74-3 CAPLUS
CN 2-Propanol, 1-[[(3-fluorophenyl)methyl]amino]-2-methyl-3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 330650-75-4 CAPLUS
CN 2-Propanol, 1-[[(4-chlorophenyl)methyl]amino]-2-methyl-3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 330650-76-5 CAPLUS
CN 2-Propanol, 1-[[(2-chlorophenyl)methyl]amino]-2-methyl-3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 330650-77-6 CAPLUS
CN 2-Propanol, 1-[[(3,4-dichlorophenyl)methyl]amino]-2-methyl-3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 330650-82-3 CAPLUS
CN 2-Propanol, 2-methyl-1-[(1-naphthalenylmethyl)amino]-3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 330650-83-4 CAPLUS
CN 2-Propanol, 2-methyl-1-[[(4-methylphenyl)methyl]amino]-3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 330650-84-5 CAPLUS
CN 2-Propanol, 1-[[(4-methoxyphenyl)methyl]amino]-2-methyl-3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 330650-85-6 CAPLUS
CN 2-Propanol, 1-[[(2-methoxyphenyl)methyl]amino]-2-methyl-3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 330650-86-7 CAPLUS
CN 2-Propanol, 1-[(2-furanylmethyl)amino]-2-methyl-3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 330650-87-8 CAPLUS
CN 2-Propanol, 2-methyl-1-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)-3-[(2-thienylmethyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 330650-88-9 CAPLUS
CN 2-Propanol, 2-methyl-1-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)-3-[(3-thienylmethyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 330650-89-0 CAPLUS

CN 2-Propanol, 2-methyl-1-[(3-pyridinylmethyl)amino]-3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 330650-90-3 CAPLUS
CN 2-Propanol, 2-methyl-1-[(2-pyridinylmethyl)amino]-3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 330650-91-4 CAPLUS
CN 2-Propanol, 2-methyl-1-[methyl(phenylmethyl)amino]-3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 330650-96-9 CAPLUS
CN 2-Propanol, 1-[(1H-benzimidazol-2-ylmethyl)amino]-3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 330650-98-1 CAPLUS
CN 2-Propanol, 1-[(4-pyridinylmethyl)amino]-3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 330651-06-4 CAPLUS
CN 2-Propanol, 1-[(cyclohexylmethyl)amino]-3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 330651-08-6 CAPLUS
CN 2-Propanol, 1-[[(4-fluorophenyl)methyl]amino]-2-methyl-3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)-, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 330651-09-7 CAPLUS
CN 2-Propanol, 1-[[(3,4-dichlorophenyl)methyl]amino]-2-methyl-3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)-, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 330651-10-0 CAPLUS
CN 2-Propanol, 1-[[(3,4-difluorophenyl)methyl]amino]-2-methyl-3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)-, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 330651-18-8 CAPLUS

CN 2-Propanol, 1-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)-3-[(3-thienylmethyl)amino]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 330651-22-4 CAPLUS
CN Benzenemethanamine, N-[(2R)-2-methoxy-3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 330651-23-5 CAPLUS
CN 2-Propanol, 1-[[(3,4-difluorophenyl)methyl]amino]-2-methyl-3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 330672-14-5 CAPLUS
CN 2-Propanol, 1-[methyl(phenylmethyl)amino]-3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT **330651-36-0P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 1-amino-3-thienoisoxazolylphenoxy-2-propanols as dopamine D4 antagonists)
RN 330651-36-0 CAPLUS
CN 2-Propanol, 1-[(phenylmethyl)amino]-3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2001:208281 CAPLUS
DOCUMENT NUMBER: 134:252333
TITLE: Preparation of N-(aralkyl)(thienoisoxazolylphenoxy)alkanamines and analogs as dopamine D4 antagonists
INVENTOR(S): Lee, George E.; Ayers, Timothy A.; Jurcak, John G.
PATENT ASSIGNEE(S): Aventis Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 108 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001019832	A2	20010322	WO 2000-US24949	20000913
WO 2001019832	A3	20011004		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,

DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

EP 1216249	A2	20020626	EP 2000-964967		20000913
EP 1216249	B1	20031119			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL					
BR 2000014513	A	20020702	BR 2000-14513		20000913
EE 200200133	A	20030415	EE 2002-133		20000913
AT 254620	E	20031215	AT 2000-964967		20000913
PT 1216249	T	20040430	PT 2000-964967		20000913
ES 2206305	T3	20040516	ES 2000-964967		20000913
ZA 2002001760	A	20030602	ZA 2002-1760		20020301
NO 2002001249	A	20020510	NO 2002-1249		20020313
PRIORITY APPLN. INFO.:			US 1999-396156	A1	19990914
			WO 2000-US24949	W	20000913

OTHER SOURCE(S): MARPAT 134:252333

AB ROZR3 [R3 = thieno[2,3-d]isoxazol-3-yl throughout][I; R = Z1NR1R2 or 1-benzyl-3-pyrrolidinyl; R1 = CH2R4, CH2CH(OH)R4, CHMeR4, indanyl, etc.; R2 = H or alkyl; NR1R2 = heterocyclyl; R4 = cyclohexenyl, (hetero)aryl, etc.; Z = phenylene; Z1 = alkylene] were prepared Thus, 3-bromothiophene was acylated by 3-(MeO)C6H4COCl and the oximated product cyclized to give, after O-demethylation, 3-R3C6H4OH which was etherified by 3-FC6H4CH2NHCOCH2Cl (preparation given) and the product reduced to give 3-R3C6H4OCH2CH2NHCH2C6H4F-3. Data for biol. activity of I were given.

IT **330678-80-3P 330678-81-4P 330678-82-5P**
330678-83-6P 330678-84-7P 330678-85-8P
330678-86-9P 330678-87-0P 330678-88-1P
330678-94-9P 330678-95-0P 330679-25-9P
330679-26-0P 330679-27-1P 330679-28-2P
330679-35-1P 330679-36-2P 330679-37-3P
330679-38-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-(aralkyl)(thienoisoxazolylphenoxy)alkanamines and analogs as dopamine D4 antagonists)

RN 330678-80-3 CAPLUS

CN Benzenemethanamine, 3-fluoro-N-[3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)propyl]- (9CI) (CA INDEX NAME)



RN 330678-81-4 CAPLUS

CN Benzenemethanamine, N-[3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)propyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 330678-82-5 CAPLUS
CN Benzenemethanamine, N-[3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)propyl]- (9CI) (CA INDEX NAME)



RN 330678-83-6 CAPLUS
CN Benzenemethanamine, 4-fluoro-N-[3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)propyl]- (9CI) (CA INDEX NAME)



RN 330678-84-7 CAPLUS
CN Benzenemethanamine, 4-chloro-N-[3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)propyl]- (9CI) (CA INDEX NAME)



RN 330678-85-8 CAPLUS
CN Benzenemethanamine, 4-methoxy-N-[3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)propyl]- (9CI) (CA INDEX NAME)



RN 330678-86-9 CAPLUS
CN 2-Thiophenemethanamine, N-[3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)propyl]- (9CI) (CA INDEX NAME)



RN 330678-87-0 CAPLUS
CN 3-Thiophenemethanamine, N-[3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)propyl]- (9CI) (CA INDEX NAME)



RN 330678-88-1 CAPLUS
CN 3-Pyridinemethanamine, N-[3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)propyl]- (9CI) (CA INDEX NAME)



RN 330678-94-9 CAPLUS
CN Benzenesulfonamide, 4-[[[3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)propyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 330678-95-0 CAPLUS
CN Benzenesulfonamide, 4-[2-[[3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)propyl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 330679-25-9 CAPLUS
CN Benzenemethanamine, 4-methyl-N-[3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)propyl]- (9CI) (CA INDEX NAME)



RN 330679-26-0 CAPLUS
CN Benzenemethanamine, 2-chloro-N-[3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)propyl]- (9CI) (CA INDEX NAME)



RN 330679-27-1 CAPLUS
CN Benzenemethanamine, 3-methoxy-N-[3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)propyl]- (9CI) (CA INDEX NAME)



RN 330679-28-2 CAPLUS
CN Benzenemethanamine, 3,4-difluoro-N-[3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)propyl]- (9CI) (CA INDEX NAME)



RN 330679-35-1 CAPLUS
CN Benzenemethanamine, 2,4-difluoro-N-[3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)propyl]- (9CI) (CA INDEX NAME)



RN 330679-36-2 CAPLUS
CN Benzenemethanamine, 2,6-difluoro-N-[3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)propyl]- (9CI) (CA INDEX NAME)



RN 330679-37-3 CAPLUS
CN Benzenemethanamine, N-[3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)propyl]-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 330679-38-4 CAPLUS
CN Benzenemethanamine, N-[3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)propyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



L8 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1987:598314 CAPLUS
DOCUMENT NUMBER: 107:198314
TITLE: Preparation of [(3-aminopropoxy)phenyl]thienoisoxazoles and- pyrazoles for treatment of hypertension and glaucoma
INVENTOR(S): Ong, Helen Hu; Yasenchak, Christine Mary
PATENT ASSIGNEE(S): Hoechst-Roussel Pharmaceuticals, Inc., USA
SOURCE: Eur. Pat. Appl., 73 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 221414	A1	19870513	EP 1986-114314	19861016
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
US 4728651	A	19880301	US 1985-791019	19851024
DK 8605079	A	19870425	DK 1986-5079	19861023
AU 8664337	A1	19870430	AU 1986-64337	19861023

JP 62103086	A2	19870513	JP 1986-250937	19861023
ZA 8608065	A	19870624	ZA 1986-8065	19861023
HU 45061	A2	19880530	HU 1986-4456	19861023
HU 198058	B	19890728		
US 4769472	A	19880906	US 1987-125108	19871125

PRIORITY APPLN. INFO.: US 1985-791019 19851024
OTHER SOURCE(S): CASREACT 107:198314
GI



I



II

AB The title compds. [I; X = O, NR; R = H, alkyl; R1 = H; R2 = alkyl, arylalkyl, aryloxyalkyl, indolylalkyl, benzodioxarylalkyl, or NR1R2 = (arylalkyl)piperazinyl] were prepared as antihypertensives and for reduction of intraocular pressure. 3-[(2-Epoxymethoxy)phenyl]-1-methyl-1H-thieno[3,2-c]pyrazole 3 g was refluxed with Me3CNH2 in EtOH for 5 h to give 2.5 g of [(aminopropoxy)phenyl]thienopyrazole derivative (II).2HCl. II reduced outflow pressure by 51% when administered to an eye as a 2% solution

IT **110894-44-5P 110894-46-7P 110894-52-5P**
110894-53-6P 110894-63-8P 110894-67-2P
110894-68-3P 110894-76-3P 110916-52-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, for treatment of hypertension and glaucoma)

RN 110894-44-5 CAPLUS
CN 2-Propanol, 1-[[2-(3,4-dimethoxyphenyl)ethyl]amino]-3-(2-thieno[2,3-d]isoxazol-3-ylphenoxy)- (9CI) (CA INDEX NAME)



RN 110894-46-7 CAPLUS
CN 2-Propanol, 1-[[2-(3,4-dimethoxyphenyl)ethyl]amino]-3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)- (9CI) (CA INDEX NAME)



RN 110894-52-5 CAPLUS
CN 2-Propanol, 1-[[(2,3-dihydro-1,4-benzodioxin-2-yl)methyl]amino]-3-(2-thieno[2,3-d]isoxazol-3-ylphenoxy)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 110894-53-6 CAPLUS
CN 2-Propanol, 1-[[2-(1H-indol-3-yl)ethyl]amino]-3-(2-thieno[2,3-d]isoxazol-3-ylphenoxy)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 110894-63-8 CAPLUS
CN 2-Propanol, 1-[[2-(3,4-dimethoxyphenyl)ethyl]amino]-3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 110894-67-2 CAPLUS
CN 2-Propanol, 1-[[2-(3,4-dimethoxyphenyl)ethyl]amino]-3-[2-(1H-thieno[3,2-c]pyrazol-3-yl)phenoxy]- (9CI) (CA INDEX NAME)



RN 110894-68-3 CAPLUS
CN 2-Propanol, 1-[[2-(3,4-dimethoxyphenyl)ethyl]amino]-3-[2-(1H-thieno[3,2-c]pyrazol-3-yl)phenoxy]-, (2E)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 110894-67-2
CMF C24 H27 N3 O4 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 110894-76-3 CAPLUS
CN 2-Propanol, 1-[[(2,3-dihydro-1,4-benzodioxin-2-yl)methyl]amino]-3-(2-thieno[2,3-d]isoxazol-3-ylphenoxy)- (9CI) (CA INDEX NAME)



RN 110916-52-4 CAPLUS
CN 2-Propanol, 1-[[2-(1H-indol-3-yl)ethyl]amino]-3-(2-thieno[2,3-d]isoxazol-3-ylphenoxy)- (9CI) (CA INDEX NAME)



=> d l9 ibib abs hitstr tot

L9 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1987:598314 CAPLUS
DOCUMENT NUMBER: 107:198314
TITLE: Preparation of [(3-aminopropoxy)phenyl]thienoisoxazoles and- pyrazoles for treatment of hypertension and glaucoma
INVENTOR(S): Ong, Helen Hu; Yasenchak, Christine Mary
PATENT ASSIGNEE(S): Hoechst-Roussel Pharmaceuticals, Inc., USA
SOURCE: Eur. Pat. Appl., 73 pp.
CODEN: EPXXDW

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 221414	A1	19870513	EP 1986-114314	19861016 <--
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
US 4728651	A	19880301	US 1985-791019	19851024 <--
DK 8605079	A	19870425	DK 1986-5079	19861023 <--
AU 8664337	A1	19870430	AU 1986-64337	19861023 <--
JP 62103086	A2	19870513	JP 1986-250937	19861023 <--
ZA 8608065	A	19870624	ZA 1986-8065	19861023 <--
HU 45061	A2	19880530	HU 1986-4456	19861023 <--
HU 198058	B	19890728		
US 4769472	A	19880906	US 1987-125108	19871125 <--

PRIORITY APPLN. INFO.: US 1985-791019 19851024
OTHER SOURCE(S): CASREACT 107:198314
GI



I



II

AB The title compds. [I; X = O, NR; R = H, alkyl; R1 = H; R2 = alkyl, arylalkyl, aryloxyalkyl, indolylalkyl, benzodioxarylalkyl, or NR1R2 = (arylalkyl)piperazinyl] were prepared as antihypertensives and for reduction of intraocular pressure. 3-[(2-Epoxymethoxy)phenyl]-1-methyl-1H-thieno[3,2-c]pyrazole 3 g was refluxed with Me3CNH2 in EtOH for 5 h to give 2.5 g of [(aminopropoxy)phenyl]thienopyrazole derivative (II).2HCl. II reduced outflow pressure by 51% when administered to an eye as a 2% solution

IT **110894-42-3P 110894-43-4P 110894-44-5P**
110894-45-6P 110894-46-7P 110894-47-8P
110894-48-9P 110894-49-0P 110894-50-3P
110894-51-4P 110894-52-5P 110894-53-6P
110894-54-7P 110894-55-8P 110894-58-1P
110894-59-2P 110894-60-5P 110894-61-6P
110894-62-7P 110894-63-8P 110894-64-9P
110894-65-0P 110894-66-1P 110894-67-2P
110894-68-3P 110894-69-4P 110894-70-7P
110894-71-8P 110894-72-9P 110894-73-0P
110894-74-1P 110894-75-2P 110894-76-3P
110894-77-4P 110916-52-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, for treatment of hypertension and glaucoma)

RN 110894-42-3 CAPLUS
CN 2-Propanol, 1-[(1,1-dimethylethyl)amino]-3-(2-thieno[2,3-d]isoxazol-3-ylphenoxy)- (9CI) (CA INDEX NAME)



RN 110894-43-4 CAPLUS
CN 2-Propanol, 1-[(1-methylethyl)amino]-3-(2-thieno[2,3-d]isoxazol-3-ylphenoxy)- (9CI) (CA INDEX NAME)



RN 110894-44-5 CAPLUS
CN 2-Propanol, 1-[[2-(3,4-dimethoxyphenyl)ethyl]amino]-3-(2-thieno[2,3-d]isoxazol-3-ylphenoxy)- (9CI) (CA INDEX NAME)



RN 110894-45-6 CAPLUS
CN 2-Propanol, 1-[(1,1-dimethylethyl)amino]-3-[2-(1-methyl-1H-thieno[3,2-c]pyrazol-3-yl)phenoxy]- (9CI) (CA INDEX NAME)



RN 110894-46-7 CAPLUS

CN 2-Propanol, 1-[[2-(3,4-dimethoxyphenyl)ethyl]amino]-3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)- (9CI) (CA INDEX NAME)



RN 110894-47-8 CAPLUS
CN 2-Propanol, 1-[(1-methyl-3-phenylpropyl)amino]-3-[2-(1-methyl-1H-thieno[3,2-c]pyrazol-3-yl)phenoxy]- (9CI) (CA INDEX NAME)



RN 110894-48-9 CAPLUS
CN 2-Propanol, 1-[(1-methyl-2-phenoxyethyl)amino]-3-[2-(1-methyl-1H-thieno[3,2-c]pyrazol-3-yl)phenoxy]- (9CI) (CA INDEX NAME)



RN 110894-49-0 CAPLUS
CN 2-Propanol, 1-[(1-methylethyl)amino]-3-(2-thieno[2,3-d]isoxazol-3-ylphenoxy)-, (2Z)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 110894-43-4
CMF C17 H20 N2 O3 S



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 110894-50-3 CAPLUS
CN 2-Propanol, 1-[(1,1-dimethylethyl)amino]-3-(2-thieno[2,3-d]isoxazol-3-ylphenoxy)-, (2Z)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 110894-42-3
CMF C18 H22 N2 O3 S



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 110894-51-4 CAPLUS
CN 2-Propanol, 1-[(1-methyl-3-phenylpropyl)amino]-3-(2-thieno[2,3-d]isoxazol-

3-ylphenoxy)- (9CI) (CA INDEX NAME)



RN 110894-52-5 CAPLUS
CN 2-Propanol, 1-[[(2,3-dihydro-1,4-benzodioxin-2-yl)methyl]amino]-3-(2-thieno[2,3-d]isoxazol-3-ylphenoxy)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 110894-53-6 CAPLUS
CN 2-Propanol, 1-[[2-(1H-indol-3-yl)ethyl]amino]-3-(2-thieno[2,3-d]isoxazol-3-ylphenoxy)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 110894-54-7 CAPLUS
CN 2-Propanol, 1-[(1-methylethyl)amino]-3-[2-(1-methyl-1H-thieno[3,2-

c]pyrazol-3-yl)phenoxy]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 110894-55-8 CAPLUS
CN 2-Propanol, 1-[(1,1-dimethylethyl)amino]-3-[2-(1-methyl-1H-thieno[3,2-c]pyrazol-3-yl)phenoxy]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 110894-58-1 CAPLUS
CN 2-Propanol, 1-[(1-methyl-3-phenylpropyl)amino]-3-[2-(1-methyl-1H-thieno[3,2-c]pyrazol-3-yl)phenoxy]-, ethanedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 110894-47-8
CMF C25 H29 N3 O2 S



CM 2

CRN 144-62-7
CMF C2 H2 O4



RN 110894-59-2 CAPLUS
CN 2-Propanol, 1-[(1-methylethyl)amino]-3-(3-thieno[2,3-b]isoxazol-3-ylphenoxy)- (9CI) (CA INDEX NAME)



RN 110894-60-5 CAPLUS
CN 2-Propanol, 1-[(1-methylethyl)amino]-3-(3-thieno[2,3-b]isoxazol-3-ylphenoxy)-, (2Z)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 110894-59-2
CMF C17 H20 N2 O3 S



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 110894-61-6 CAPLUS
CN 2-Propanol, 1-[(1,1-dimethylethyl)amino]-3-(3-thieno[2,3-d]isoxazol-4-ylphenoxy)- (9CI) (CA INDEX NAME)



RN 110894-62-7 CAPLUS
CN 2-Propanol, 1-[(1,1-dimethylethyl)amino]-3-(3-thieno[2,3-d]isoxazol-4-ylphenoxy)-, (2Z)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 110894-61-6
CMF C18 H22 N2 O3 S



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 110894-63-8 CAPLUS
CN 2-Propanol, 1-[[2-(3,4-dimethoxyphenyl)ethyl]amino]-3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 110894-64-9 CAPLUS
CN 2-Propanol, 1-[(1-methylethyl)amino]-3-(4-thieno[2,3-d]isoxazol-3-ylphenoxy)- (9CI) (CA INDEX NAME)



RN 110894-65-0 CAPLUS
CN 2-Propanol, 1-[(1-methylethyl)amino]-3-(4-thieno[2,3-d]isoxazol-3-ylphenoxy)-, (2Z)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 110894-64-9
CMF C17 H20 N2 O3 S



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 110894-66-1 CAPLUS
CN 2-Propanol, 1-[(1,1-dimethylethyl)amino]-3-(4-thieno[2,3-d]isoxazol-3-ylphenoxy)- (9CI) (CA INDEX NAME)



RN 110894-67-2 CAPLUS
CN 2-Propanol, 1-[[2-(3,4-dimethoxyphenyl)ethyl]amino]-3-[2-(1H-thieno[3,2-c]pyrazol-3-yl)phenoxy]- (9CI) (CA INDEX NAME)



RN 110894-68-3 CAPLUS
CN 2-Propanol, 1-[[2-(3,4-dimethoxyphenyl)ethyl]amino]-3-[2-(1H-thieno[3,2-c]pyrazol-3-yl)phenoxy]-, (2E)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 110894-67-2
CMF C24 H27 N3 O4 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 110894-69-4 CAPLUS
CN 2-Propanol, 1-[(1-methyl-2-phenoxyethyl)amino]-3-[2-(1H-thieno[3,2-c]pyrazol-3-yl)phenoxy]- (9CI) (CA INDEX NAME)



RN 110894-70-7 CAPLUS
CN 2-Propanol, 1-[(1-methyl-2-phenoxyethyl)amino]-3-[2-(1H-thieno[3,2-c]pyrazol-3-yl)phenoxy]-, (2Z)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 110894-69-4
CMF C23 H25 N3 O3 S



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 110894-71-8 CAPLUS
CN 2-Propanol, 1-[[2-(2-methoxyphenoxy)ethyl]amino]-3-[2-(1-methyl-1H-thieno[3,2-c]pyrazol-3-yl)phenoxy]- (9CI) (CA INDEX NAME)



RN 110894-72-9 CAPLUS
CN 2-Propanol, 1-[[2-(2-methoxyphenoxy)ethyl]amino]-3-[2-(1-methyl-1H-thieno[3,2-c]pyrazol-3-yl)phenoxy]-, (2E)-2-butenedioate (2:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 110894-71-8
CMF C24 H27 N3 O4 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 110894-73-0 CAPLUS
CN 2-Propanol, 1-[[2-(2-methoxyphenoxy)-1-methylethyl]amino]-3-[2-(1-methyl-1H-thieno[3,2-c]pyrazol-3-yl)phenoxy]- (9CI) (CA INDEX NAME)



RN 110894-74-1 CAPLUS
CN 2-Propanol, 1-[[2-(2-methoxyphenoxy)-1-methylethyl]amino]-3-[2-(1-methyl-1H-thieno[3,2-c]pyrazol-3-yl)phenoxy]-, (2Z)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 110894-73-0
CMF C25 H29 N3 O4 S



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 110894-75-2 CAPLUS
CN 2-Propanol, 1-[(1-methylethyl)amino]-3-[3-(1-methyl-1H-thieno[3,2-c]pyrazol-3-yl)phenoxy]- (9CI) (CA INDEX NAME)



RN 110894-76-3 CAPLUS
CN 2-Propanol, 1-[[(2,3-dihydro-1,4-benzodioxin-2-yl)methyl]amino]-3-(2-thieno[2,3-d]isoxazol-3-ylphenoxy)- (9CI) (CA INDEX NAME)



RN 110894-77-4 CAPLUS
CN 2-Propanol, 1-[(1-methylethyl)amino]-3-[2-(1-methyl-1H-thieno[3,2-c]pyrazol-3-yl)phenoxy]- (9CI) (CA INDEX NAME)



RN 110916-52-4 CAPLUS
CN 2-Propanol, 1-[[2-(1H-indol-3-yl)ethyl]amino]-3-(2-thieno[2,3-d]isoxazol-3-ylphenoxy)- (9CI) (CA INDEX NAME)



=> d l10 ibib abs hitstr tot

L10 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1987:598314 CAPLUS
DOCUMENT NUMBER: 107:198314
TITLE: Preparation of [(3-aminopropoxy)phenyl]thienoisoxazoles and- pyrazoles for treatment of hypertension and glaucoma
INVENTOR(S): Ong, Helen Hu; Yasenchak, Christine Mary
PATENT ASSIGNEE(S): Hoechst-Roussel Pharmaceuticals, Inc., USA
SOURCE: Eur. Pat. Appl., 73 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
EP 221414	A1	19870513	EP 1986-114314	19861016	<--
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE					
US 4728651	A	19880301	US 1985-791019	19851024	<--
DK 8605079	A	19870425	DK 1986-5079	19861023	<--
AU 8664337	A1	19870430	AU 1986-64337	19861023	<--
JP 62103086	A2	19870513	JP 1986-250937	19861023	<--
ZA 8608065	A	19870624	ZA 1986-8065	19861023	<--
HU 45061	A2	19880530	HU 1986-4456	19861023	<--
HU 198058	B	19890728			
US 4769472	A	19880906	US 1987-125108	19871125	<--
PRIORITY APPLN. INFO.:			US 1985-791019	19851024	

OTHER SOURCE(S): CASREACT 107:198314
GI



I



II

AB The title compds. [I; X = O, NR; R = H, alkyl; R1 = H; R2 = alkyl, arylalkyl, aryloxyalkyl, indolylalkyl, benzodioxarylalkyl, or NR1R2 = (arylalkyl)piperazinyl] were prepared as antihypertensives and for reduction of intraocular pressure. 3-[(2-Epoxymethoxy)phenyl]-1-methyl-1H-thieno[3,2-c]pyrazole 3 g was refluxed with Me3CNH2 in EtOH for 5 h to give 2.5 g of [(aminopropoxy)phenyl]thienopyrazole derivative (II).2HCl. II reduced outflow pressure by 51% when administered to an eye as a 2% solution

IT **110894-44-5P 110894-46-7P 110894-52-5P**
110894-53-6P 110894-63-8P 110894-67-2P
110894-68-3P 110894-76-3P 110916-52-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, for treatment of hypertension and glaucoma)

RN 110894-44-5 CAPLUS

CN 2-Propanol, 1-[[2-(3,4-dimethoxyphenyl)ethyl]amino]-3-(2-thieno[2,3-d]isoxazol-3-ylphenoxy)- (9CI) (CA INDEX NAME)



RN 110894-46-7 CAPLUS

CN 2-Propanol, 1-[[2-(3,4-dimethoxyphenyl)ethyl]amino]-3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)- (9CI) (CA INDEX NAME)



RN 110894-52-5 CAPLUS

CN 2-Propanol, 1-[[(2,3-dihydro-1,4-benzodioxin-2-yl)methyl]amino]-3-(2-thieno[2,3-d]isoxazol-3-ylphenoxy)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 110894-53-6 CAPLUS
CN 2-Propanol, 1-[[2-(1H-indol-3-yl)ethyl]amino]-3-(2-thieno[2,3-d]isoxazol-3-ylphenoxy)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 110894-63-8 CAPLUS
CN 2-Propanol, 1-[[2-(3,4-dimethoxyphenyl)ethyl]amino]-3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 110894-67-2 CAPLUS
CN 2-Propanol, 1-[[2-(3,4-dimethoxyphenyl)ethyl]amino]-3-[2-(1H-thieno[3,2-c]pyrazol-3-yl)phenoxy]- (9CI) (CA INDEX NAME)



RN 110894-68-3 CAPLUS
CN 2-Propanol, 1-[[2-(3,4-dimethoxyphenyl)ethyl]amino]-3-[2-(1H-thieno[3,2-c]pyrazol-3-yl)phenoxy]-, (2E)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 110894-67-2
CMF C24 H27 N3 O4 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 110894-76-3 CAPLUS
CN 2-Propanol, 1-[[(2,3-dihydro-1,4-benzodioxin-2-yl)methyl]amino]-3-(2-thieno[2,3-d]isoxazol-3-ylphenoxy)- (9CI) (CA INDEX NAME)



RN 110916-52-4 CAPLUS
CN 2-Propanol, 1-[[2-(1H-indol-3-yl)ethyl]amino]-3-(2-thieno[2,3-d]isoxazol-3-ylphenoxy)- (9CI) (CA INDEX NAME)



=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	29.20	362.33

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-3.50	-5.60

STN INTERNATIONAL LOGOFF AT 09:08:44 ON 21 OCT 2004